.
An Open-Label Multicenter Randomized .
03 mayo 2010
Yondelis in Metastatic Breast Cancer Patients With Triple Negative Profile (ER-, PR-, HER2-), HER2 Overexpressing Tumors and BRCA1 or BRCA2 Mutation
.
Phase II, Multicenter, Open-label.
Phase II, Multicenter, Open-label.
Yondelis for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment .
.
A Multicenter, Open-label Single-arm .
A Multicenter, Open-label Single-arm .
Suscribirse a:
Entradas (Atom)